FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Pharmaceutically Acceptable Salts topics
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Dimethyl Fumarate
Amelioration
Antivirals
Prophylaxis
Antiviral Agent
Antiviral Agents
Hepatitis C
Benzimidazole
Hepatitis C Virus
Neurodegenerative Disease
Neurodegenerative Diseases
Multiple Sclerosis
Degenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Pharmaceutically Acceptable Salts patents



      
           
This page is updated frequently with new Pharmaceutically Acceptable Salts-related patents. Subscribe to the Pharmaceutically Acceptable Salts RSS feed to automatically get the update: related Pharmaceutically RSS feeds.

Subscribe to updates on this page: Pharmaceutically Acceptable Salts RSS RSS

Date/App# patent app List of recent Pharmaceutically Acceptable Salts-related patents
04/10/14
20140100369
 Pyrrolopyridines as kinase inhibitors patent thumbnailnew patent Pyrrolopyridines as kinase inhibitors
Compounds of formula i are useful for inhibition of chk1 and/or chk2. Methods of using compounds of formula i and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
04/10/14
20140100366
 Process for making thienopyrimidine compounds patent thumbnailnew patent Process for making thienopyrimidine compounds
And stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof.. .
04/10/14
20140100231
 Non-nucleoside reverse transcriptase inhibitors patent thumbnailnew patent Non-nucleoside reverse transcriptase inhibitors
Are hiv reverse transcriptase inhibitors, wherein r1, r2, re, l, m and z are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.
04/03/14
20140094474
 Androgen receptor modulating carboxamides patent thumbnailAndrogen receptor modulating carboxamides
Wherein rx, rz, r9, r10, r14, r14′, r15, r15′, a and b are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (sarm) and are useful as medicaments in the treatment of prostate cancer and other ar dependent conditions and diseases where ar antagonism is desired..
04/03/14
20140094459
 Tyrosine kinase inhibitors patent thumbnailTyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof..
04/03/14
20140094446
 Cyclic amino acids for the treatment of pain patent thumbnailCyclic amino acids for the treatment of pain
Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said compositions are for use in the treatment of pain.
04/03/14
20140094403
 Enopeptins, uses thereof, and methods of synthesis thereto patent thumbnailEnopeptins, uses thereof, and methods of synthesis thereto
Provided herein are inventive enopeptin compounds of formula (i): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment..
04/03/14
20140094402
 Lantibiotic nai-802, pharmaceutically acceptable salts, compositions and uses thereof patent thumbnailLantibiotic nai-802, pharmaceutically acceptable salts, compositions and uses thereof
The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.. .
04/03/14
20140093570
 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein patent thumbnailSolid oral formulations and crystalline forms of an inhibitor of apoptosis protein
The present disclosure relates to crystalline form of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluorobenzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same..
04/03/14
20140093566
 Pharmaceutical formulations of a substituted diaminopurine patent thumbnailPharmaceutical formulations of a substituted diaminopurine
Provided herein are pharmaceutical formulations, comprising 4-((9-((3s)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9h-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.. .
03/27/14
20140088184
Use of epigallocatechin gallate as an antiviral agent against infections by the hepatitis c virus
The present invention relates to a flavonoid compound having the formula i, where r3, r5 and/or r7 is a group having the formula ii, or r1 and r2 are both oh groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis c virus (hcv) infection. The invention also relates to an ex vivo method for reducing the infectivity of hcv or for inactivating hcv, including a step of contacting said hepatitis c virus with a compound having the formula (i)..
03/27/14
20140088155
D-methadone for the treatment of psychiatric symptoms
The present invention relates to a method of treating psychiatric symptoms in a subject having a nmda receptor and a ne receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the nmda receptor and ne receptor of the subject.. .
03/27/14
20140088144
Inhibiting microbial infections
A method of inhibiting a microbial infection can include: providing a compound of the invention or prodrugs or pharmaceutically acceptable salts thereof; and administering the compound to a subject in a therapeutically effective amount to inhibit the microbial infection. The therapeutically effective amount can be sufficient to inhibit a biological activity of a transcriptional activator of the microbe.
03/27/14
20140088130
Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (i) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor.
03/27/14
20140088126
Rosuvastatin enantiomer compounds
The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including aids, cancer, and alzheimer's disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3r, 5r), (3s, 5r), or (3s, 5s) configurations, or pharmaceutically acceptable salts thereof.
03/27/14
20140088121
Hsp90 inhibitors
And pharmaceutically acceptable salts thereof wherein z1, z2, z3, xa, xb, xc, xd, y, x2, and x4 are as defined herein, compositions comprising an effective amount of a compound of formula (ia) and/or (ib), and methods to treat or prevent a condition, such cancer which overexpresses her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a compound of formula (ia) or (ib). The disclosure further relates to compounds of formulae (ia) and ib) in which x2 is a leaving for introducing a radiolabeled atom, such as 124i or 131i and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging..
03/27/14
20140088117
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
03/27/14
20140088114
Fused bicyclic kinase inhibitors
Compounds of formula (i), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of met, ron, alk, ir, or igf-1r. This abstract is not limiting of the invention..
03/27/14
20140088104
Novel small-molecules as therapeutics
The present invention provides compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression..
03/27/14
20140088097
Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
And the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.. .
03/27/14
20140088081
Amino-heterocyclic compounds
And pharmaceutically acceptable salts thereof, wherein r1, r2, r3, a, and n are as defined herein. Pharmaceutical compositions containing the compounds of formula i, and uses thereof in treating neurodegenerative and cognitive disorders, such as alzheimer's disease and schizophrenia, are also provided..
03/27/14
20140088063
Agents for treating neurodegenerative disorders
Wherein r, x and n are as defined in specification or pharmaceutically acceptable salts thereof, solvates thereof such as hydrates, and pharmaceutical compositions containing such compounds, with the proviso that the compound of formula (i) is not meso-1s,2s,1′r,2′r-1-[2-(3,3-dimethyldiaziridin-1-yl)ethyl]-3,3-dimethyldiaziridine (r═me, x═ch2, n=2) (formula i′).. .
03/27/14
20140088062
Compositions comprising fusidic acid and packages therefor
Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases..
03/27/14
20140086981
Pgc-1alpha-modulating peptides
Peptides of general formula (i): r1—wn—xm-aa1-aa2-aa3-aa4-aa5-aa6-yp—zq—r2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases which improve or are prevented by pgc-1α modulation.. .
03/27/14
20140086837
F-18 radiolabeled compounds for diagnosing and monitoring kidney function
The invention relates to 18f-labeled compounds of formula (i), hydrates, isomers, or pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions. The invention relates to the methods of diagnosing kidney function in humans by pet imaging..
03/20/14
20140081022
Modulators of toll-like receptors
Pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.. .
03/20/14
20140080881
Liquid formulations of bendamustine
Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.. .
03/20/14
20140080876
Antimicrobial and radioprotective compounds
The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (i), in which x and y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms x and y; r1 to r5 are either the same or different and selected from hydrogen or a non-deleterious substituent; and r6 and r7 are either the same or different and selected from hydrogen and a non-deleterious substituent or one of r6 and r7 are absent when there is a double bond present, pharmaceutically acceptable salts or derivatives, pro-drugs, tautomers and/or isomers thereof. The present invention also relates to a method for protecting a subject from radiation damage, a method of cancer radiotherapy and use as an antimicrobial or radioprotective agent of the compound of formula (i) defined above.
03/20/14
20140080832
Ire-1alpha inhibitors
Compounds which directly inhibit ire-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies..
03/20/14
20140080810
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
The invention is directed to compounds of formula i: (i) and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens.. .
03/20/14
20140080806
Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
The present invention provides, inter alia, compounds of formula (i) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of formula (id) and pharmaceutically acceptable salts thereof as cyp3a4 selective inhibitors..
03/20/14
20140080801
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
03/20/14
20140080790
Heteroarylcarboxylic acid ester derivative
Wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.. .
03/20/14
20140079834
Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
The present invention relates to bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals.
03/20/14
20140079784
Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
This invention provides specifically formulated lfa-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the lfa-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate.
03/20/14
20140079783
Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients.
03/20/14
20140079730
Composition comprising vlp and amyloid beta peptide
The present invention relates to novel uses of a construct consisting of virus-like particle (vlp) structure chemically coupled to a fragment of the a□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter construct), in particular to dosage regimens, modes of and dosage forms for the administration of a construct for the treatment of patients suffering from dementia. In particular dementia of the a.
03/20/14
20140079647
Cefdinir and cefixime formulations and uses thereof
The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages.
03/20/14
20140076036
Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers
The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof.
03/13/14
20140073782
Substituted quinazoline and pyrido-pyrimidine derivatives
The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds.
03/13/14
20140073688
Compounds for use in the treatment of filariasis
Or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of the general formula (1), a nematicidal composition comprising as an active ingredient a compound according to the general formula (1), and a method for treating filariasis.. .
03/13/14
20140073669
4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
Provided are 4′-o substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed..
03/13/14
20140073667
Deuterated cftr potentiators
And pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a cftr potentiator..
03/13/14
20140073629
Alkoxy pyrazoles as soluble guanylate cyclase activators
And pharmaceutically acceptable salts thereof, wherein r1, r2, r3, r4, r5, r6 and r7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes..
03/13/14
20140073628
Benzoxazepines asn inhibitors of p13k/m tor and methods of their use and manufacture
The invention is directed to inhibitors of mtor and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula i and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein..
03/13/14
20140073626
Azaindole derivatives as tyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, jak3, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts..
03/13/14
20140073584
Thienopyranones as kinase inhibitors
The invention relates to compounds of formula i (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as pi-3 kinase.. .
03/13/14
20140072628
Stable pharmaceutical composition of saxagliptin
Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.. .
03/06/14
20140066622
Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
And pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.. .
03/06/14
20140066449
Dipyridinium derivatives
Compounds of formula (i): α-x-β (i) and pharmaceutically acceptable salts and solvates thereof, wherein α, x, and β have the meanings as indicated in the specification, are useful for treating a disease or disorder characterised by pathologically proliferating cells, particularly cancer. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described..
03/06/14
20140066431
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
The invention is directed to compounds of formula i: and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens.. .
03/06/14
20140066404
Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
The present invention provides pyrazole derivative compounds and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of preventing and treating osteoporosis..
03/06/14
20140066369
Modulators of the gpr119 receptor and the treatment of disorders related thereto
The present invention relates to compounds of formula i and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a dpp-iv inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an sglt2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a gpr119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.. .
02/27/14
20140058129
Phenylacetic acid derivatives
Pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of cox-2 dependent disorders.. .
02/27/14
20140058116
Process for preparing inhibitors of the hepatitis c virus
The present invention relates to synthetic processes useful in the preparation of compounds of formula (i) that are useful as inhibitors of the hepatitis c virus (hcv) ns3 protease and have application in the treatment of conditions caused by hcv. In particular, the present invention relates to novel oxidation processes useful for preparing compounds of formula (i) and related compounds, including pharmaceutically acceptable salts, hydrates and solvates thereof, and including stereoisomers thereof..
02/27/14
20140058103
Inhibitors of pi3k-delta and methods of their use and manufacture
The invention is directed to compounds of formula i: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.. .
02/27/14
20140058098
Benzoxazepin pi3k inhibitor compounds and methods of use
Benzoxazepin compounds of formula i, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: z1 is cr1 or n; z2 is cr2 or n; z3 is cr3 or n; z4 is cr4 or n; and b is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of pi3k, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
02/27/14
20140057989
Polyamine transporter selective compounds as anti cancer agents
Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells.
02/27/14
20140057988
Anxiolytic composition, formulation and method of use
A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an nmda receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The nmda receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication.
02/27/14
20140057981
Self-emulsifying composition of omega3 fatty acid
This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property.
02/27/14
20140057938
Kat ll inhibitors
Wherein x, y, z, r1, r2, r3, r4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.. .
02/27/14
20140057932
1,3-dioxanomorphides and 1,3-dioxanocodides
And pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein g, r2-r5, and are defined as set forth in the specification. The invention is also directed to use of compounds of formula i as synthetic intermediates or to treat disorders responsive to the modulation of one or more opiopid receptors.
02/27/14
20140057896
Pyridone and aza-pyridone compounds and methods of use
Pyridone and aza-pyridone compounds of formula i are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
02/27/14
20140057893
Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
Substituted cyclopropyl compounds of the formula i: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the g-protein coupled receptor gpr-119.
02/27/14
20140057886
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
And pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.. .
02/20/14
20140052049
Method of treating onychomycosis
This application is directed to a method of treating onychomycosis by applying a phototherapeutic agent to a nail structure, waiting for a period of at least three days, and exposing the nail to light that causes an activation reaction. The phototherapeutic agent may be amino levulinic acid, alkylated derivatives of ala, and their pharmaceutically acceptable salts..
02/20/14
20140051854
Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular rosuvastatin and pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used dibal-h as reducing agent can be avoided..
02/20/14
20140051757
Therapeutical method for the treatment of the leber optic neuropathy
It is described the use of l-carnitine and/or one or more alkanoyl l-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the leber optic neuropathy.. .
02/20/14
20140051755
Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.. .
02/20/14
20140051728
Dabigatran in tumor therapy
Optionally in the form of the pharmaceutically acceptable salts thereof, as well as new medicament formulations which may be used for this purpose.. .
02/20/14
20140051722
Topical lfa-1 antagonists for use in localized treatment of immune related disorders
This invention provides specifically formulated lfa-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the lfa-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate.
02/20/14
20140051715
3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
Wherein x is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents.
02/20/14
20140051714
Modulators of the gpr119 receptor and the treatment of disorders related thereto
The present invention relates to the gpr119 agonist, 4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)-5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidine (compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a dpp-iv inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an sglt2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a gpr119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.. .
02/20/14
20140051695
Novel inhibitor compounds of phosphodiesterase type 10a
The compounds of the formula i, the n-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10a and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.. .
02/20/14
20140051686
3-arylamino pyridine derivatives
Pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein w, r1, r2, r9, r10, r11, r12, r13, r14 are as defined in the specification. Such compounds are mek inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation.
02/20/14
20140051629
Modulators of the gpr119 receptor and the treatment of disorders related thereto
The present invention relates to the gpr119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-n,n-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoro-propan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-n-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a dpp-iv inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an sglt2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a gpr119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.. .


Popular terms: [SEARCH]

Pharmaceutically Acceptable Salts topics: Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Dimethyl Fumarate, Amelioration, Antivirals, Prophylaxis, Antiviral Agent, Antiviral Agents, Hepatitis C, Benzimidazole, Hepatitis C Virus, Neurodegenerative Disease, Neurodegenerative Diseases, Multiple Sclerosis, Degenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Pharmaceutically Acceptable Salts for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmaceutically Acceptable Salts with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4993

5241

1 - 1 - 76